• 1
    Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8: S4S66.
  • 2
    Auvinen A, Rietbergen JB, Denis LJ, Schröder FH, Prorok PC. Prospective evaluation plan for randomized trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen. 1996; 3: 97104.
  • 3
    Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA. 1993; 270: 948954.
  • 4
    American Cancer Society. Available from URL: Site area=CRI [accessed July 1, 2003].
  • 5
    Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol. 1997; 158: 18861890.
  • 6
    Hoedemaeker RF, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001; 93: 11531158.
  • 7
    Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol. 1998; 59: 920924.
  • 8
    Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason Grade 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason score 4 + 3 and 3 + 4 independent of the number of involved cores. J Urol. 2002; 167: 24402442.
  • 9
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003; 21: 21632172.
  • 10
    Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001; 166: 104109.
  • 11
    Ravery V, Chastang C, Toublanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod L. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol. 2000; 37: 449455.
  • 12
    Hoedemaeker RF, Rietbergen JB, Kranse R, Kwast TH, Schröder FH. Are impalpable and invisible tumors clinically important? World J Urol. 1997; 15: 339345.
  • 13
    Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, Fifth Edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80: 18031804.
  • 14
    Gilliand FD, Gleason DF, Hunt WC, Stone N, Harlan LC, Key CR. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. J Urol. 2001; 165: 846850.
  • 15
    Farkas A, Schneider D, Perotti M, Cummings B, Ward WS. National trends in epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998; 52: 444448; discussion, 448–449.
  • 16
    Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, Kwast TH. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000; 164: 411415.
  • 17
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868878.
  • 18
    Carter HB, Pearson JD, Metter AJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267: 22152220.
  • 19
    Van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst. 2003; 95: 14621466.